Blood coagulation and fibrinolysis in eclamptic patients and their correlation with the clinical signs.
We studied the impact of blood coagulation and fibrinolysis on the clinical features of eclamptic patients (n = 20) in Bangladesh. The variables used were edema, proteinuria, blood pressure, number of convulsions, level of consciousness at the time of admission, thrombin antithrombin complexes (TAT), antithrombin (AT) III (%) activity and antigen, D dimer fibrin degradation product and alpha 2-plasmin inhibitor-plasmin complex (PIC) in plasma. Canonical correlation analysis was made to obtain clinical index, eclampsia index and two coagulation indices. On admission, the mean values of coagulation parameters were AT III activity: 83.2% (range 57-108), TAT complex: 47.6 ng/ml (range 11.5-60), D dimer: 1,693 ng/ml (range 417-8,276) and PIC 1.4 mg/ml (range 0.4-3.3). We found a significant correlation between the eclampsia index and clinical index (r = 0.601; p = 0.01). Gestosis index, clinical index, and eclampsia index have also a strong correlation with the coagulation index (r = 0.695, p < 0.005; r = 0.871, p < 0.0001 and r = 0.805, p < 0.0001, respectively). Coagulation and fibrinolysis were markedly activated in eclampsia. The correlation between the clinical status and coagulation status in this study suggested a close relation between the coagulation and the development and progression of the disease.
Halim
A
A
Department of Obstetrics and Gynecology, Hamamatsu University School of Medicine, Japan.
Bhuiyan
A B
AB
Azim
F A
FA
Khatun
S
S
Kanayama
N
N
el Maradny
E
E
Maehara
K
K
Hiroshi
K
K
Terao
T
T
D000293:Adolescent; D000328:Adult; D000933:Antifibrinolytic Agents / Q000097:blood*; D000990:Antithrombin III / Q000032:analysis*; D004461:Eclampsia / Q000097:blood*; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis*; D005341:Fibrinolysin / Q000378:metabolism*; D006801:Humans; D010447:Peptide Hydrolases / Q000032:analysis*; D011247:Pregnancy; D012720:Severity of Illness Index; D013223:Statistics as Topic; D000979:alpha-2-Antiplasmin
D000933:Antifibrinolytic Agents; D005338:Fibrin Fibrinogen Degradation Products; D000979:alpha-2-Antiplasmin; C046193:antithrombin III-protease complex; C036309:fibrin fragment D; C037742:plasmin-plasmin inhibitor complex; D000990:Antithrombin III; D010447:Peptide Hydrolases; D005341:Fibrinolysin